About Adaptive Biotechnologies
Adaptive Biotechnologies (NASDAQ:ADPT) is a biotech firm specializing in the genetics of the adaptive immune system to develop clinical products and services aimed at diagnosing, treating, and managing diseases more precisely. The company leverages its proprietary immune medicine platform to decode the information carried by the immune system, harnessing it for medical diagnosis and treatment, particularly in cancer, autoimmune conditions, and infectious diseases. With a focus on innovative research and development, Adaptive Biotechnologies is committed to advancing the understanding of the immune system’s role in health and disease, aiming to improve patient outcomes through precision medicine. Their projects range from clinical diagnostics to drug discovery, striving to translate the complexity of the immune system into actionable solutions for patients and healthcare providers.
Snapshot
Operations
Products and/or services of Adaptive Biotechnologies
- T-cell receptor (TCR) sequencing: They sequence and analyze the unique genetic makeup of T-cells, crucial for immune response.
- ClonoSEQ® assay: This proprietary test identifies and characterizes antigen-specific T-cells, aiding in immune monitoring and drug development
- Immune repertoire analysis tools: They provide software and bioinformatics tools to analyze and interpret T-cell receptor sequencing data.
- Discovery and development of immune therapies: They leverage their T-cell expertise to discover and develop novel immunotherapies for cancer and other diseases.
- Collaboration with pharmaceutical and biotechnology companies: They partner with other companies to advance their immunotherapy platforms and drug discovery efforts.
- Clinical trials: They conduct and participate in clinical trials to evaluate the safety and efficacy of their T-cell based therapies.
Adaptive Biotechnologies executive team
- Mr. Chad M. Robins M.B.A.Co-Founder, CEO & Chairman
- Ms. Julie RubinsteinPresident & COO
- Dr. Harlan S. Robins Ph.D.Co-Founder & Chief Scientific Officer
- Mr. Kyle PiskelVP, CFO & Principal Accounting Officer
- Dr. Sharon Benzeno Ph.D.Chief Commercial Officer of Immune Medicine
- Mr. Christopher Carlson Ph.D.Founder
- Ms. Karina CalzadillaVice President of Investor Relations
- Ms. Clarice McCauleyInterim General Counsel, Corporate Secretary, VP & Chief Compliance Officer
- Mr. Francis T. LoChief People Officer
- Ms. Susan BobulskyChief Commercial Officer of MRD